Patient Stories|VPRIV® (velaglucerase alfa) for injection

FEEL EMPOWERED TO PRESCRIBE
VPRIV AS A FIRST-LINE TREATMENT
FOR YOUR TYPE 1 GAUCHER PATIENTS

Make VPRIV your choice for patients during various stages of life.^1,2

MATEO

Name: Mateo
Age: 20
Age at type 1 Gaucher diagnosis: 15
Ethnicity: Hispanic
Treatment history: VPRIV, 5 years
Symptoms at baseline: Moderately low hemoglobin, mildly enlarged spleen, reduced bone density³
Last check-up: Maintained improvements in hemoglobin count and spleen volume^1,4,5

^*Not an actual patient. This is a hypothetical patient profile.

Name: Mateo
Age: 20
Age at type 1 Gaucher diagnosis: 15
Ethnicity: Hispanic
Treatment history: VPRIV, 5 years
Symptoms at baseline:
Moderately low hemoglobin, mildly enlarged spleen, reduced bone density³
Last check-up:
Maintained improvements in hemoglobin count and spleen volume^1,4,5

Once Mateo was diagnosed with type 1 Gaucher disease as a teenager, his parents and physician came up with a treatment plan. After discussing the risks and benefits, they chose VPRIV as his treatment. Mateo received infusions at the hospital for the first 6 months and then transitioned to home infusions.⁴

When Mateo was 18 years old he moved away from his home in Miami, Florida, to attend university in New York City. Mateo and his parents planned for this transition and found an infusion center near his campus. He was able to schedule his infusions around his classes and settle into his new treatment schedule.

Consider

VPRIV can be infused in multiple settings, including at infusion centers and hospitals. Patients can also work with their HCPs to arrange for infusions to be taken at home.
Young adults are able to change infusion sites when going to college or moving away from home.

Looking to start your patients on VPRIV? Start the process by downloading a OnePath^® Start Form and filling it in with your patients to begin. Please contact OnePath^® at 1-866-888-0660 with any questions.

VPRIV OnePath® Start Form

Download the full VPRIV Patient Profiles here.

VPRIV Patient Profiles

VPRIV
Clinical Trials

Safety &
Tolerability Profile

Takeda Support Programs

STAY CONNECTED!

Fill in the required fields to stay up to date with news and announcements about VPRIV.

FIRST NAME*

LAST NAME*

EMAIL ADDRESS*

*By checking this box and clicking “Submit,” you certify that you are at least 18 years old, a US resident, and you are opting to receive information about VPRIV and other information from Takeda. You will be able to opt out of these communications using the unsubscribe feature.

Takeda respects your personal information. All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our Privacy Notice Statement. We encourage you to read our Privacy Notice Statement. This consent will be in effect until such a time as you opt out of the program.

FEEL EMPOWERED TO PRESCRIBE VPRIV AS A FIRST-LINE TREATMENT FOR YOUR TYPE 1 GAUCHER PATIENTS

Consider

FEEL EMPOWERED TO PRESCRIBE
VPRIV AS A FIRST-LINE TREATMENT
FOR YOUR TYPE 1 GAUCHER PATIENTS